MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study-Reference-Cited by-同舟云学术

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Published:2014-05 Issue:6 Volume:15 Page:656-666
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hong David S,Hui David,Bruera Eduardo,Janku Filip,Naing Aung,Falchook Gerald S,Piha-Paul Sarina,Wheler Jennifer J,Fu Siqing,Tsimberidou Apostolia M,Stecher Michael,Mohanty Prasant,Simard John,Kurzrock Razelle

Publisher

Elsevier BV

Subject

Oncology

Reference44 articles.

1. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review;Solheim;Acta Oncol,2013

2. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases;Dinarello;Nat Rev Drug Discov,2012

3. IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasis;Matsuo;J Surg Oncol,2009

4. Interleukin-1 alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications;Matsuo;J Surg Res,2009

5. IL-1 is required for tumor invasiveness and angiogenesis;Voronov;Proc Natl Acad Sci USA,2003

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

2. Understanding cachexia and its impact on lung cancer and beyond;Chinese Medical Journal Pulmonary and Critical Care Medicine;2024-06

3. Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series;Journal of Cachexia, Sarcopenia and Muscle;2024-05-23

4. Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions;Cancers;2024-04-27

5. Exploring the multifaceted effects of Interleukin-1 in lung cancer: From tumor development to immune modulation;Life Sciences;2024-04